Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia

International Journal of Hematology

Volumn 95, Issue 3, 2012, Pages 285-290

  Celik, Serkan ^a   Sayan, Ozkan ^a   Oktenli, Cagatay ^b   Ozari, H Onur ^a   Terekeci, M Hakan ^a   Kilicaslan, Emrah ^a   Ipcioglu, Osman ^a   Erikci, Alev A ^a   Tangi, Fatih ^a   Sanisoglu, Yavuz S ^c  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b Anadolu Medical Center   (Turkey)

^c YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

Acute myeloid leukemia; MEFV gene; Myelodysplastic syndrome

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILIAL MEDITERRANEAN FEVER; FAMILY HISTORY; GENE; GENE FREQUENCY; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MEFV GENE; MYELODYSPLASTIC SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; CYTOSKELETAL PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; YOUNG ADULT;

EID: 84862985409     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1022-0     Document Type: Article

References (44)

1. Terekeci HM, Ulusoy ER, Kucukarslan NM, Nalbant S, Oktenli C. Familial Mediterranean fever attacks do not alter functional and morphologic tissue Doppler echocardiographic parameters. Rheumatol Int. 2008;28:1239-43.
2. Terekeci HM, Oktenli C, Ozgurtas T, Nalbant S, Top C, Celik S, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol. 2008;35:2024-9.
3. Musabak U, Sengul A, Oktenli C, Pay S, Yesilova Z, Kenar L, et al. Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin Exp Immunol. 2004;138:526-33. (Pubitemid 39573635)
4. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25-31.
5. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797-807.
6. Touitou I. Infevers Database. http://fmf.igh.cnrs.fr/ISSAID/infevers/ search.php?n=1.
7. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9:473-83. (Pubitemid 32750487)
8. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95:3223-31. (Pubitemid 30321178)
9. Koc B, Oktenli C, Bulucu F, Karadurmus N, Sanisoglu SY, Gul D. The rate of pyrin mutations in critically ill patients with systemic inflammatory response syndrome and sepsis: a pilot study. J Rheumatol. 2007;34:2070-5.
10. Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med. 2004;200: 551-8. (Pubitemid 39258304)
11. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell. 2003;11:591-604. (Pubitemid 36385116)
12. Dowds TA, Masumoto J, Chen FF, Ogura Y, Inohara N, Nunez G. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun. 2003;302:575-80. (Pubitemid 36279569)
13. Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al. Fire and ICE: the role of pyrin domain containing proteins in inflammation and apoptosis. Clin Exp Rheumatol. 2002;20:S45-53.
14. Manji GA, Wang L, Geddes BJ, Brown M, Merriam S, Al-Garawi A, et al. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem. 2002;277:11570-5. (Pubitemid 34952928)
15. Stehlik C, Krajewska M, Welsh K, Krajewski S, Godzik A, Reed JC. The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated NF-jB and pro-caspase-1 regulation. Biochem J. 2003;373:101-13. (Pubitemid 36819506)
16. Stehlik C, Fiorentino L, Dorfleutner A, Bruey JM, Ariza EM, Sagara J, et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med. 2002;196:1605-15. (Pubitemid 36026472)
17. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1b processing. Cell Death Differ. 2007;14: 1457.
18. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheum. 2005;17: 586.
19. Keutgens A, Robert I, Viatour P, Chariot A. Deregulated NF-jB activity in haematological malignancies. Biochem Pharmacol. 2006;72:1069-80. (Pubitemid 44479739)
20. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol. 2004;41:6-12. (Pubitemid 38649813)
21. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, et al. NF-jB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107:1156-65. (Pubitemid 43156318)
22. Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol. 2000;111:873-4. (Pubitemid 32098925)
23. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004;18:466-75. (Pubitemid 38425860)
24. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985-90. (Pubitemid 28227550)
25. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol. 2001;73:429-37. (Pubitemid 33758875)
26. Tidow N, Chen X, Muller C, Kawano S, Gombart AF, Fischel- Ghodsian N, et al. Hematopoietic-specific expression of MEFV,the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood. 2000;95: 1451-5. (Pubitemid 30099860)
27. Oktenli C, Sayan O, Celik S, Erikci AA, Tunca Y, Terekeci HM, et al. High frequency of MEFV gene mutations in patients with myeloid neoplasm. Int J Hematol. 2010;91:758-61.
28. Celik S, Erikci AA, Tunca Y, Sayan O, Terekeci HM, Umur EE, et al. The rate of MEFV gene mutations in hematolymphoid neoplasms. Int J Immunogenet. 2010;37:387-91.
29. Medlej-Hashim M, Serre JL, Corbani S, Saab O, Jalkh N, Delague V, et al. Familial Mediterranean fever (FMF) in Lebanon and Jordan: a population genetics study and report of three novel mutations. Eur J Med Genet. 2004;48:412.
30. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25:387-408. (Pubitemid 44922357)
31. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222: 222-41. (Pubitemid 351430377)
32. Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor jB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92:1124-9.
33. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35:1739-46. (Pubitemid 47633781)
34. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-jB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106:3917-25. (Pubitemid 41739032)
35. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-jB in hematologic malignancies. Cell Death Differ. 2006;13:748-58.
36. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NF-jB activation via pharmacologic inhibition of IKK2 induced apoptosis of human acute myeloid leukaemia cells. Blood. 2005;105:804-11. (Pubitemid 40070768)
37. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-jB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood. 2001;98:2301-7.
38. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16: 2062-71. (Pubitemid 35203449)
39. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, et al. Expression of constitutively active nuclear-kB RelA transcription factor in blasts of acute myeloid leukaemia. Hum Pathol. 2003;35:246-53.
40. Sanz C, Richard C, Prosper F, Fernandez-Luna JL. Nuclear factor jB is activated in myelodysplastic bone marrow cells. Haematologica. 2002;87:1005-6.
41. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107:2112-22. (Pubitemid 43289397)
42. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998;92: 3090-7. (Pubitemid 28492314)
43. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, et al. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999;94:2844-53. (Pubitemid 29477313)
44. Grateau G, Pecheux C, Cazeneuve C, Cattan D, Dervichian M, Goossens M, et al. Clinical versus genetic diagnosis of familial Mediterranean fever. Q J Med. 2000;93:223-9. (Pubitemid 30198959)